Physician profile
Andrew E Azer
NPI 1235387507
$3,674.07
in general payments reported to CMS, 2019-2025
29 companies · $898 in 2025
The $898 reported for 2025 was more than what 77% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $346 · 2021: $444 · 2022: $200 · 2023: $563 · 2024: $649 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,035.97 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $574.55 | 2019-2025 | |
| Glaxosmithkline, LLC. | $459.62 | 2019-2025 | Nucala |
| Optinose US, INC. | $374.62 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $356.07 | 2019-2025 | Dupixent |
| Aerin Medical INC. | $350.83 | 2023-2025 | |
| Csl Behring | $316.22 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Stryker Corporation | $149.64 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $128.70 | 2022-2025 | Fasenra, Tezspire |
| Kaleo, INC. | $124.47 | 2020-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $122.04 | 2020-2025 | Eohilia, Cuvitru |
| Alk-Abello, INC | $90.42 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $89.49 | 2021-2023 | |
| Grifols USA, LLC | $83.15 | 2024-2025 | Xembify |
| Hikma Pharmaceuticals USA | $68.84 | 2024-2025 | Ryaltris |
| Acclarent, INC | $54.39 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $39.45 | 2019 | |
| Octapharma USA, INC. | $36.65 | 2019-2021 | |
| Ambu INC. | $34.67 | 2023 | |
| Amgen INC. | $32.11 | 2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $29.18 | 2021 | |
| Shire North American Group INC | $29.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.72 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $18.75 | 2025 | Xhance |
| Smith+Nephew, INC. | $17.38 | 2025 | Tula |
| Bio Products Laboratory USA, INC. | $15.09 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.21 | 2019 | |
| Merck Sharp & Dohme LLC | $13.03 | 2021 | |
| Incyte Corporation | $12.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Azer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.